Did Earnings Beat Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
ANIP Q3 2026 deep dive: rare disease expansion and Cortrophin bottlenecks shape outlook
ANI Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Is ANI Pharmaceuticals (ANIP) A Bargain After Its $560m Deal?
ANI Pharmaceuticals (ANIP) Offers $560 Million For Rare Disease Expansion
Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows?
ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript
Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121
ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Offset ...
ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
ANI Pharmaceuticals Q3 Earnings Call Highlights
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026
ANI: Q3 Earnings Snapshot
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
ANI Pharmaceuticals Q3 2026 Earnings Call Transcript
ANI Pharmaceuticals Q3 Adj. EPS $2.70 Beats $2.18 Estimate, Sales $290.800M Beat $280.196M Estimate
ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.